• Explore /
  • Poster
  • / A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388).

A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388).

Abstract Poster

Authors

Ulka Vaishampayan

Ulka N. Vaishampayan

Wayne State University, Detroit, MI

Ulka N. Vaishampayan , Edwin J. De Wit , Neal D. Shore , Robert Dreicer , Daniel J. George , Ralph V. Boccia , Brendan D. Curti , Lajos Geczi , Tibor Csõszi , Nicholas J. Vogelzang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04028388

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS268)

Abstract #

TPS268

Poster Bd #

P12

Abstract Disclosures

Similar Posters

First Author: Ulka N. Vaishampayan

First Author: Daniel Petrylak

First Author: Ulka N. Vaishampayan

First Author: Ulka N. Vaishampayan